Home Crystal structure of 4,4-dimethyl-2-(trifluoromethyl)-4,5-dihydro-1H-imidazole, C6H9F3N2
Article Open Access

Crystal structure of 4,4-dimethyl-2-(trifluoromethyl)-4,5-dihydro-1H-imidazole, C6H9F3N2

  • A. Musa Said EMAIL logo , Ismail Warad EMAIL logo , O. Seraj Alzahrani , Abdelkader Zarrouk and Dieter Lentz EMAIL logo
Published/Copyright: February 4, 2019

Abstract

C6H9F3N2, monoclinic, P21/n (no. 14), a = 10.6224(9) Å, b = 11.8639(9) Å, c = 13.3139(11) Å, β = 105.903(3)°, V = 1613.6(2) Å3, Z = 8, Rgt(F) = 0.0618, wRref(F2) = 0.1629, T = 102(2) K [1–3].

CCDC no.: 1884790

The crystal structure is shown in the figure. Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal:Colourless block
Size:0.40 × 0.20 × 0.18 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:0.13 mm−1
Diffractometer, scan mode:Bruker Venture Photon, φ and ω
θmax, completeness:27.6°, >99%
N(hkl)measured, N(hkl)unique, Rint:25043, 3722, 0.029
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 3126
N(param)refined:211
Programs:Bruker [1], SHELX [2], [3]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
C10.6367(2)0.27964(17)0.58791(15)0.0254(4)
C20.73966(18)0.44033(16)0.63748(15)0.0220(4)
C30.6742(2)0.40100(18)0.72269(16)0.0281(4)
H3A0.7390690.3954470.7918990.034*
H3B0.6031630.4528850.7276000.034*
C40.5809(3)0.1758(2)0.52623(18)0.0413(6)
C50.6921(2)0.55617(19)0.59481(18)0.0333(5)
H5A0.7293850.5749080.5372310.050*
H5B0.7198900.6124390.6503790.050*
H5C0.5963560.5558710.5693130.050*
C60.8882(2)0.4379(2)0.67844(19)0.0346(5)
H6A0.9167670.3619090.7034660.052*
H6B0.9164640.4917230.7360640.052*
H6C0.9270060.4584850.6221560.052*
C70.40653(17)0.18527(15)0.85401(14)0.0181(4)
C80.22696(18)0.08125(16)0.77486(14)0.0214(4)
C90.31326(19)0.11170(18)0.70118(15)0.0241(4)
H9A0.3492570.0424710.6780590.029*
H9B0.2606520.1521880.6387050.029*
C100.49772(19)0.25035(17)0.94148(14)0.0232(4)
C110.0969(2)0.1437(2)0.74606(18)0.0326(5)
H11A0.0528680.1326470.8010530.049*
H11B0.0416040.1143490.6798150.049*
C120.2065(2)−0.04492(18)0.78123(18)0.0350(5)
H12A0.291734−0.0826100.8040800.053*
H12B0.158469−0.0734030.7122990.053*
H12C0.156267−0.0602020.8314290.053*
F10.6175(4)0.08556(15)0.57764(17)0.1328(15)
F20.4514(2)0.1738(2)0.5063(2)0.1104(11)
F30.6078(2)0.16886(14)0.43734(13)0.0660(6)
F40.58725(15)0.30726(13)0.90982(10)0.0436(4)
F50.56104(13)0.18335(11)1.01875(10)0.0353(3)
F60.43133(14)0.32464(12)0.98252(11)0.0413(4)
N10.69927(17)0.35430(14)0.55252(13)0.0246(4)
H1N0.567(3)0.259(3)0.706(2)0.051(9)*
N20.6232(2)0.2912(17)0.68486(15)0.0371(5)
H2N0.283(3)0.137(2)0.928(2)0.036(7)*
N30.31069(16)0.12340(15)0.87538(13)0.0252(4)
N40.42054(16)0.18443(13)0.76162(12)0.0207(3)

Source of material

Stoichiometric amount of 2-methylpropane-1,2-diamine (1.68 g, 19.06 mmol) was dissolved in 50 mL of dioxone in one neck round bottom flask equipped with a reflux condenser and magnetic stirring bar. Ethyl 2,2,2-trifluoroacetate (2.71 mL, 3.97 g, 38.12 mmol) was added dropwise and the mixture was stirred at moderate heating (50 °C) overnight. The solvent was completely removed and viscous colorless product was obtained. The product was further purified by distillation under reduced pressure (0.1 mm Hg, RT), (Yield 79%). M.P. 55−57 °C.

Experimental details

Hydrogen atoms were placed at the calculated positions and included using a riding model with Uiso(H) = 1.2Ueq or 1.5Ueq of the adjacent non-hydrogen atom.

Comment

The development of imidazole-based molecules has speedily increased recently, since it can be used extensively in medicinal chemistry as man-made drugs, agrochemicals, artificial acceptors, biomimetic catalysts, supramolecular material [4], [5], [6]. Several imidazole medicinal drugs have been used for treatment of broad types of diseases, imidazole derivatives demonstrated anti-inflammatory, analgesic, antiviral, anti-tubercular, antimicrobial, antimalarial, anti-diabetic and anticancer activity [7], [8], [9], [10].

The molecule C6H9F3N2 crystallizes in the space group P21/n. The asymmetric unit of the title structure contains two independent molecules (figure), with a high similarity in their structural parameters like bond lengths and angles. The similarity of these two structures extends to their hydrogen-bonding motifs. The molecules in the title structure are connected via intermolecular hydrogen bonds, of N—H⋯N type (N2⋯N4: 2.91 Å; N1⋯N3′: 2.93 Å; ′ = 0.5 + x, 0.5 − y, −0.5 + z).

Acknowledgements

M. A. Said is thankful to Alexander von Humboldt Stiftung, Germany for the opportunities provided.

References

1. Bruker. APEX2, SAINT and SADABS. Bruker AXS Inc., Madison, WI, USA (2009).Search in Google Scholar

2. Sheldrick, G. M.: SHELXT – Integrated space-group and crystal-structure determination. Acta Crystallogr. A71 (2015) 3–8.10.1107/S2053273314026370Search in Google Scholar PubMed PubMed Central

3. Sheldrick, G. M.: SHELXL-2017/1. Acta Crystallogr. C71 (2015) 3–8.10.1107/S2053229614024218Search in Google Scholar PubMed PubMed Central

4. Forte, B.; Malgesini, B.; Piutti, C.; Quartieri, F.; Scolaro, A.; Papeo, G.: A submarine journey: the pyrrole-imidazole alkaloids. Drugs 7 (2009) 705–753.10.3390/md7040705Search in Google Scholar PubMed PubMed Central

5. Jin, Z.: Muscarine, imidazole, oxazole, and thiazole alkaloids. Nat. Prod. Rep. 28 (2011) 1143–1191.10.1039/c0np00074dSearch in Google Scholar PubMed

6. Jiang, H.; Zhou, C.; Luo, K.; Chen, H.; Lan, J.; Xie, R.: Chiral imidazole metalloenzyme models: synthesis and enantioselective hydrolysis for α-amino acid esters. J. Mol. Catal. A: Chem. 260 (2006) 288–294.10.1016/j.molcata.2006.07.034Search in Google Scholar

7. Congiu, C.; Cocco, M.; Onnis, V.: Design, synthesis, and in vitro antitumor activity of new 1,4-diarylimidazole-2-ones and their 2-thione analogues. Bioorg. Med. Chem. Lett 18 (2008) 989–993.10.1016/j.bmcl.2007.12.023Search in Google Scholar PubMed

8. Venkatesan, A. M.; Agarwal, A.; Abe, T.; Ushirogochi, H.; Ado, M.; Tsuyoshi, T.; Santos, O. D.; Li, Z.; Francisco, G.; Lin, Y. I.; Peterson, P. J.; Yang, Y.; Weiss, W. J.; Shales, D. M.; Manzour, T. S.: 5,5,6-Fused tricycles bearingimidazole and pyrazole 6-methylidene penems as broad-spectrum inhibitors of β-lactamases. Bioorg. Med. Chem. 16 (2008) 1890–1902.10.1016/j.bmc.2007.11.006Search in Google Scholar PubMed

9. Bizhayev, M.: Biological activities of the natural imidazole-containing peptidomimetics n-acetylcarnosine, carcinine and L-carnosine in ophthalmic and skin care products. Life Sci. 78 (2006) 2343–2357.10.1016/j.lfs.2005.09.054Search in Google Scholar PubMed

10. Roman, G.; Riley, J.; Vlahakis, J.; Kinobe, R.; Brien, J.; Nakatsu, K.; Szrek, W.: Heme oxygenase inhibition by 2-oxy-substituted 1-(1H-imidazol-1-yl)-4-phenylbutanes: effect of halogen substitution in the phenyl ring. Bioorg. Med. Chem. 15 (2007) 3225–3234.10.1016/j.bmc.2007.02.034Search in Google Scholar PubMed

Received: 2018-12-14
Accepted: 2019-01-15
Published Online: 2019-02-04
Published in Print: 2019-03-26

©2019 A. Musa Said et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 Public License.

Articles in the same Issue

  1. Cover and Frontmatter
  2. Crystal structure of poly[aqua-μ2-4,4′-bis(pyrid-4-yl)biphenyl-κ2N:N′)-μ4-4′-methyl-[1,1′-biphenyl]-3,5-dicarboxylato-κ4O:O′:O′′:O′′′)manganese(II)], C52H40N2O10Mn2
  3. Crystal structure of bis[2-(((3-aminopropyl)imino)methyl)-4-nitro-phenolato-κ3N,N′,O]nickel(II), C20H24N6NiO6
  4. Synthesis and crystal structure of bis{2-((E)-((4-((E)-1-(methoxyimino)ethyl)phenyl)imino)methyl) phenolato-κ2N,O}cobalt(II) — ethanol (1/1), C34H36CoN4O5
  5. Crystal structure of 1-(4-{2,5-dichloro-3-hydroxy-4-[4-(1-methoxyimino-ethyl)-phenylamino]-6-methyl-phenylamino}-phenyl)-ethanone O-methyl-oxime, C24H22Cl2N4O4
  6. The pseudosymmetric crystal structure of 2,4,6,8,10,12-hexanitrohexaazaisowurtzitane dimethyl carbonate (2/3), C21H30N24O33
  7. Crystal structure of (1,4-diazepane)4CuII2(μ-Cl)10CuI6, C20H48Cl10Cu8N8
  8. Crystal structure of methyl 2,7,7-trimethyl-4-(3-methylthiophen-2-yl)-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, C19H23NO3S
  9. Crystal structure of methyl 2-(4-(pyrazolo[1,5-a]pyrimidin-6-yl)phenyl)acetate, C15H13N3O2
  10. Crystal structure of (1S,3aR,3bR,10aR,10bR,12aR)-8-amino-3a,3b,6,6,10a-pentamethyl-1-((S)-2,6,6-trimethyltetrahydro-2H-pyran-2-yl)-2,3,3a,3b,4,5,5a,6,10,10a,10b,11,12,12a-tetradecahydro-1H-cyclopenta[7,8]phenanthro[2,3-d]thiazol-12-ol – a panaxadiol dervative, C31H50N2O2S
  11. Crystal structure of bis[(((4-fluorophenyl)amino)methyl)triphenylphosphonium] tetrachloridocobaltate(II), C50H44Cl4CoF2N2P2
  12. Crystal structure of 5,4′-dihydroxy-7,3′-dimethoxyflavanone, C17H16O6
  13. Crystal structure of 3-methyl-cyclobis(1-(1,1′-ferrocenylmethyl)-4-butyl-1H-1,2,3-triazole) tetrafluoroborate, C21H25FeN6⋅BF4
  14. Crystal structure of 3-(2-diethylaminoethyl)-2,3-dihydro-2-thioxoquinazolin-4(1H)-one, C14H19N3OS
  15. Crystal structure of 2-(bis(3,5-dimethylphenyl) ((methyldiphenylsilyl)oxy)methyl) pyrrolidine, C34H39NOSi
  16. The crystal structure of 1,4-dinitro-2,3,5,6-tetraacetoxy-piperazine, C12H16N4O12
  17. Crystal structure of rac-3,6-dimethyl-5-(prop-1-en-2-yl)-6-vinyl-1,4,5,6-tetrahydro-2H-indol-2-one, C15H19NO
  18. Crystal structure of (Cu0.51In0.49)tet[Cr1.74In0.26]octSe4 selenospinel, Cu0.51In0.75Cr1.74Se4
  19. Crystal structure of 7-hydroxy-5-methoxy-4,6-dimethylisobenzofuran-1(3H)-one, C11H12O4
  20. Crystal structure of trans-tetrakis(acetonitrile-κN)bis(triphenylphosphine-κP)ruthenium(II) dihexafluorophosphate - dichloroform (1/2), C46H44Cl6F12N4P4Ru
  21. Crystal structure of 2-((4-nitrophenyl)thio)ethan-1-ol, C8H9NO3S
  22. Crystal structure of diaqua-dichlorido-bis(μ3-6,6′-(hydrazine-1,2-diylidenebis(methanylylidene))bis(2-methoxyphenolato)κ6O,N:N′,O′,O′:O′′)trizinc(II) - ethanol (1/2), C36H44Cl2N4O12Zn3
  23. Crystal structure of the co-crystal 2-[(2-carboxyphenyl)disulfanyl]benzoic acid – 3-chlorobenzoic acid (2/1), C35H25ClO10S4
  24. The crystal structure of 4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-ol, C15H11ClFN3O2
  25. Crystal structure of ethyl (E)-1-(3-ethoxy-3-oxoprop-1-en-1-yl)-2-(4-nitrophenyl)-2,5-dihydro-1H-benzo[b][1,4]diazepine-3-carboxylate, C23H23N3O6
  26. Crystal structure of (E)-2-(4-cyanophenyl)ethenesulfonyl fluoride, C9H6FNO2S
  27. Crystal structure of bis(4-bromo-2-(((3-chloropropyl)imino)methyl)phenolato-κ2N,O)-oxidovanadium(IV), C20H20Br2Cl2N2O3V
  28. The crystal structure of 1,1,1,3,3,3-hexaphenyldistannoxane – 2,2′-bipyridine (1/1), C46H38N2OSn2
  29. Crystal structure of coordination polymer catena-poly[diaqua-(2,6-dichloropyridine-4-carboxyliato-κ2O,O′)-bis(μ2-2,6-dichloropyridine-4-carboxyliato-κ2O:O′)terbium(III), C18H10Cl6N3O8Tb
  30. The crystal structure of 4-((2-(4,5-dihydro-1,5-diphenyl-1H-pyrazol-3-yl)anthracen-10-yl) methyl)morpholine, C34H31N3O
  31. The crystal structure of bis(N,N-dimethylformamide-κO)-tetrakis(9H-xanthene-9-carboxylic-carboxylate-κ2O:O′)dicopper(II) - acetonitrile (1/2), C66H56Cu2N4O14
  32. Crystal structure of trans-dichlorido-(1,3-dimesityl-1H-imidazol-2(3H)-ylidene)-(5-methyl-3,4-dihydro-2H-pyrrole-κN)palladium(II), C25H31Cl2N3OPd
  33. Crystal structure of 8,8′-di-p-tolyl-8′H-7,8′-biacenaphtho[1,2-d]imidazole, C40H26N4
  34. The crystal structure of 3-amino-(2,4-dioxopent-3-yl)-4,5-dihydro-1,2,4-triazinium nitrate, C8H13N5O5
  35. Crystal structure of 4,4′,5,5′-tetraphenyl-2,2′-di-p-tolyl-2′H-1,2′-biimidazole, C44H34N4
  36. Halogen bonds in the crystal structure of 2-bromo-1,10-phenanthroline – 1,4-diiodotetrafluorobenzene (2/1), C30H14Br2F4I2N4
  37. Crystal structure of tris(1-phenyl-1,2-propanedione-2-oximato-κ2N,O)cobalt(III), C27H24N3O6Co
  38. Crystal structure of chlorido-(6,6′-((1,2-phenylenebis(azanylylidene))bis(methanylylidene))bis(3-methoxyphenolato)-κ4O,N,N′,O′)iron(III), C22H18ClN2FeO4
  39. Crystal structure of bis(μ2-1-(4-chlorophenyl)-3-phenyl-4-thenoyl-1H-pyrazol-5-olato-κ3O,O′:O′)-bis-(1-(4-chlorophenyl)-3-phenyl-4-thenoyl-1H-pyrazol-5-olato-κ2O,O)-bis(ethyl acetate-κO)dicadmium(II), C88H64Cl4N8O12S4Cd2
  40. Crystal structure of catena-poly[dichlorido-(μ2-3-(2-pyridyl)-4-(4-pyridyl)-5-(3-pyridyl)-1,2,4-triazole-κ2N:N′)] copper(II), C17H12N6Cl2Cu
  41. Crystal structure of dichlorido-([2,2′:6′,2′′-terpyridine]-4′-carboxylic acid-κ3N,N′,N′′)copper(II) monohydrate, C16H13Cl2CuN3O3
  42. Crystal structure of triethylammonium(5-carboxypyridine-2-thiolato-κ2N,S)-bis(dimethylsulfoxide-κ1S)-(6-sulfidonicotinato-κ2N,S)ruthenium(II) trihydrate, C22H41N3O9RuS4
  43. The crystal structure of poly[(μ5-2,5-dicarboxy-benzoato-κ4O:O:O′:O′′,O′′′)silver(I)], C9H5AgO6
  44. Crystal structure of (E)-1-(thiophen-2-yl)-N-(5-((triphenylstannyl)thio)-1,3,4-thiadiazol-2-yl)methanimine, C25H19N3S3Sn
  45. Crystal structure of diaqua-bis(3,5-dichloroisonicotinato-κ1O)-bis(1,3-di(pyridin-4-yl)propane-κ1N)cobalt(II), C38H36Cl4N6O6Co
  46. Crystal structure of dodecaaqua-bis(μ2-4,4′-bipyridine-κ2N:N′)-bis(4,4′-((5-carboxylato-1,3-phenylene)bis(oxy))dibenzoato-κ1O)tricopper(II) - water (1/4), C62H70Cu3N4O32
  47. Crystal structure of bis(5-methoxy-2-(((2-oxidoethyl)imino)methyl)phenolate-κ3O,N,O′)manganes(IV), C20H22N2O6Mn
  48. Crystal structure of tetramethylammonium (2-(3-ethoxy-2-oxidobenzylidene)-1-(2-hydroxybenzoyl)hydrazin-1-ido-κ3N,N′,O)cobalt(III), C36H40N5O8Co
  49. Crystal structure of 6-cyclohexyl-6,7-dihydrodibenzo[c,f][1,5]azabismocin-12(5H)-yl nitrate, C20H23O3N2Bi
  50. Crystal structure of (E)-N-((2S,3S,4R,10R,13S, 17S)-17-(1-(dimethylamino) ethyl)-2,4-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)-2-methylbut-2-enamide, C24H48N2O3
  51. Crystal structure of (E)-2-((4-chlorophenyl)(phenyl)methylene)hydrazine-1-carbothioamide, C14H12ClN3S
  52. Crystal structure of 1-benzyl-3-cyano-6-phenyl-1,2-dihydropyridine, C19H16N2
  53. Isolation and crystal structure of 4-((2-(methoxycarbonyl)phenyl)amino)-2-methyl-4-oxobutanoic acid from Delphinium Grandiflorum, C13H15N1O5
  54. Crystal structure of tetraqua-bis(4-(hydroxymethyl)benzoato-κO)nickel(II), C16H22O10Ni
  55. Crystal structure of ajacisine D monohydrate, C30H44N2O9
  56. The crystal structure of (E)-4-(1-(2-aminophenylimino)ethyl)benzene-1,3-diol, C14H14N2O2
  57. Crystal structure of poly[(μ4-(4H-1,2,4-triazol-4-yl)phenyl)acetato-κ4N,N′,O,O′)(formiato-κ1O)cobalt(II)], C11H9CoN3O4
  58. The crystal structure of bis tetrabutylammonium bis(μ3-2,2,2-tri(hydroxymethyl)ethyl-4-((3-methoxy-3-oxopropyl)amino)-4-oxobutanoato)-(μ6-oxido)-hexakis(μ2-oxido)-hexaoxido-hexavanadium(V), C58H112N4O29V6
  59. Crystal structure of (N-benzylpropane-1,3-diamine-κ2N, N′)(2,2′-bipyridine-κ2N,N′)platinum(II) chloride, C20H24Cl2N4Pt
  60. Crystal structure of 5-(5-(4-chlorophenyl)-1-phenyl-1H-pyrazol-3-yl)-N-phenyl-2-amine, C23H16ClN5O
  61. Crystal structure of poly-[(μ2(carboxylatomethyl)((3-nitrophenyl)sulfonyl)amido-κ3N: O:O′)(μ2-4,4′-bipyridine-κ2N:N′)copper(II)], C18H14CuN4O6S
  62. Crystal structure of poly-[(μ2-(carboxylatomethyl)((3-nitrophenyl)sulfonyl)amido-κ3N:O:O′)(μ2-4,4′-bipyridine-κ2N:N′) nickel(II)], C18H14NiN4O6S
  63. Crystal structure of N-((3R,10S,13S,17S)-17-((S)-1-(dimethylamino)ethyl)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)-N-methylbenzamide, C31H48N2O
  64. The crystal structure of dichloroido(1,3-bis(2,6-dimethyl-phenyl)-1H-3l4-imidazol-2-yl)(2-methyl-4,5-dihydrooxazol-κN)palladium(IV)-water (1/1), C23H29Cl2N3O2Pd
  65. Crystal structure of catena-poly[dibromido-{μ2-1,5-dimethyl-2-phenyl-4-((pyridin-4-ylmethylene)amino)-1,2-dihydro-3H-pyrazol-3-one-κ2N:O}zinc(II)], C34H32Br4N8O2Zn2
  66. Crystal structure of diaqua-dichlorido-bis(μ2-2-(((1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)imino)methyl)phenolato-κ4O:O,N,O′)dicobalt(II), C36H36Cl2N6O6Co2
  67. Crystal structure of catena-poly[diaqua-(μ2-1,2-bis(4-pyridinyl)ethyane-κ2N:N′)-(μ2–pyridazine-4,5-dicarboxylato-κ2O:O′)]dizinc(II) dihydrate, C12H12ZnN3O6
  68. The crystal structure of 2-(4-chloro-2,6-dinitrophenyl)-1-(4-chloro)diazene oxide, C12H6Cl2N4O5
  69. Crystal structure of 2-isopropylthioxanthone, C16H14OS
  70. Crystal structure of methyl 2-(4-(3-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl)phenyl)acetate, C19H17N5O2
  71. Crystal structure of 4,4-dimethyl-2-(trifluoromethyl)-4,5-dihydro-1H-imidazole, C6H9F3N2
  72. Crystal structure of N-methylanilinium 5,7-dihydroxy-4-oxo-2-phenyl-4H-chromene-8-sulfonate monohydrate, C22H21NO8S
  73. Crystal structure of methyl 4-acetoxybenzoate, C10H10O4
  74. Crystal structure of catena-poly[(bis(μ-1,1′-[(5-methoxy-2,4,6-trimethyl-1,3-phenylene)bis(methylene)]bis(1H-1,2,4-triazole)-κ2N:N′)-bis(isothiocyanato-κN)manganese(II)], C34H40MnN14O2S2
  75. Crystal structure of N-(2-methylphenyl)(propan-2-yloxy)carbothioamide, C11H15NOS
Downloaded on 30.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2018-0582/html
Scroll to top button